Valuation: Fulcrum Therapeutics, Inc.

Market Cap 291M 255M 240M 219M 410M 27.85B 413M 2.88B 1.12B 14.2B 1.09B 1.07B 46.03B P/E 2026 *
-6.2x
P/E 2027 * -6.89x
Enterprise Value -13.91M -12.21M -11.47M -10.49M -19.6M -1.33B -19.75M -138M -53.43M -679M -52.23M -51.08M -2.2B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week-0.13%
Current month-3.21%
1 month-1.95%
3 months+0.13%
6 months-43.81%
Current year-66.71%
1 week 3.75
Extreme 3.75
3.86
1 month 3.75
Extreme 3.75
3.92
Current year 2.83
Extreme 2.83
12.03
1 year 2.83
Extreme 2.83
15.74
3 years 2.32
Extreme 2.315
15.74
5 years 2.25
Extreme 2.25
29.12
10 years 2.25
Extreme 2.25
33.1
Manager TitleAgeSince
Chief Executive Officer 59 2023-06-30
Director of Finance/CFO 64 2023-08-06
Chief Tech/Sci/R&D Officer 63 2022-11-30
Director TitleAgeSince
Director/Board Member 71 2016-07-18
Director/Board Member 71 2016-07-18
Chairman 50 2022-01-09
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/26
Tang Capital Management LLC
BuyCompany 50,945 0.0765%
7/15/26
Tang Capital Management LLC
BuyCompany 107,377 0.1611%
7/13/26
Tang Capital Management LLC
OtherCompany 6,663,383 10.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-0.13%-54.36%-10.36% 291M
+1.46%+4.59%+8.65%+31.91% 47.56B
+1.77%+1.10%+50.30%+34.60% 44.09B
-2.22%+0.96%+8.19%+87.44% 41.5B
+1.16%-1.92%+343.62%+554.75% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
+0.08%+0.41%+24.21%+152.44% 17.23B
+2.05%+1.09%+25.56%+41.98% 15.06B
+1.25%-5.68% - - 14.65B
-1.29%-5.60%-4.25% - 13.82B
Average +0.22%+0.67%+44.78%+117.35% 26.48B
Weighted average by Cap. +0.42%+0.96%+71.08%+143.78%

Financials

2026 *2027 *
Net sales - -
Net income -47.04M -41.29M -38.81M -35.48M -66.31M -4.51B -66.8M -466M -181M -2.3B -177M -173M -7.45B -44M -38.62M -36.3M -33.19M -62.02M -4.21B -62.48M -436M -169M -2.15B -165M -162M -6.97B
Net Debt -305M -267M -251M -230M -429M -29.18B -433M -3.02B -1.17B -14.88B -1.14B -1.12B -48.23B -296M -260M -245M -224M -418M -28.39B -421M -2.94B -1.14B -14.48B -1.11B -1.09B -46.93B
Logo Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. In addition to its product candidates, the Company has developed a discovery approach to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. It also presented preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrating tumor growth inhibition in castration resistant prostate cancer models.
Employees
9
Date Price Change Volume
26-09-24 US$3.765 -1.18% 860,524
26-09-23 US$3.810 -0.78% 1,194,425
26-09-22 US$3.840 +1.05% 978,964
26-09-21 US$3.800 +1.06% 731,534
26-09-18 US$3.760 -0.27% 3,656,213
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
3.810USD
Average target price
3.667USD
Spread / Average Target
-3.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FULC Stock